Status
Conditions
About
Using DNA acquired from tumor tissue, sequencing and PNA-clamping for EGFR gene will be performed. The detection rates of EGFR mutation will be compared using paired samples.
Full description
Single arm, open label, prospective, observational study of gefitinib treatment for locally advanced (stage IIIB) or IV (metastatic) or relapsed NSCLC patients.
Using DNA acquired from tumor tissue, sequencing and PNA-clamping for EGFR gene will be performed. The detection rates of EGFR mutation will be compared using paired samples.
Enrollment
Sex
Volunteers
Inclusion criteria
Exclusion criteria
140 participants in 1 patient group
Loading...
Central trial contact
Ju-Mi Yoon, MS; Young-Chul Kim, MD, PhD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal